

## Special Issue

# Tuberculosis and Latent Tuberculosis Infection: Molecular Basis and Translational Research

### Message from the Guest Editors

Though effective treatment has been available for more than sixty years, tuberculosis (TB) remains one of the deadly infectious diseases worldwide. Early diagnosis and treatment are crucial to prevent transmission and reduce mortality. However, many aspects of TB pathogenesis and transmission are still unclear, preventing accurate diagnosis and effective intervention. More translational research works for the management of TB are urgently needed. Another critical element in TB control is preventive therapy for latent TB infection (LTBI). Correct diagnosis and safe, short treatment both contribute to the effectiveness of LTBI intervention programs and public acceptance. With the introduction of interferon-gamma release assay (IGRA) and rifapentine, a long-acting rifamycin drug, there has been tremendous improvement in the implementation of LTBI programs. However, current clinical practice for LTBI is far from optimal. There are still many research gaps concerning the molecular basis of host immune response against TB bacilli and adverse drug reactions, as well as short, safe, and personalized treatment.

---

### Guest Editors

Dr. Jann-Yuan Wang  
Dr. Horng-Yunn Dou  
Dr. Abhishek Mishra

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/94299](https://mdpi.com/si/94299)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).